Repercussions of the Use of Imiquimod in Genital Warts

Abstract

Introduction: The manifestations of a sexually transmitted infection such as condyloma acuminatum generated by the HPV virus are reflected in the increase in the prevalence curve in women and men. 

Objective: To analyze the effectiveness of Imiquimod on anogenital warts in immunocompetent women and men. Methods: The search strategy was made in PubMed, Scielo, LILACS and Google Scholar, Scopus, Trip Database. only 13 articles entered. 

Results: Sauder et al, 2003 Imiquimod at 5%, efficacy in women and men 72% and 33% respectively. Baker et al, 2011 efficacy Imiquimod 2.5% 28.3%, Imiquimod 3.75% 36.6%. Trofater et al, 2002 with frequency of administration of 5% Imiquimod 1 time per day, 2 times per day and 3 times per week efficacy of 72%, 63% and 62% respectively. Komericki et al, 2011podophyllotoxin with Imiquimod, podophyllotoxin efficacy 72%, Imiquimod 75%. Aricano et al, 2014 Imiquimod efficacy 69.7%. Gilson et al, 2020 Imiquimod plus vaccine efficacy 56%, Podophyllotoxin plus vaccine 54%, Imiquimod plus placebo50%, podophyllotoxin plus placebo 56%. Garland et al, 2006 Imiquimod efficacy 51.6%. Gollnick et al, 2001 efficacy of Imiquimod at 5% 61.8% 3 times a week and 56.7% once a day. Edwards et al, 1998 efficacy of Imiquimod at 5% 72% women and 33% men at 1% efficacy in women 38% and men 7%. 

Conclusions: Imiquimod has been shown to be a drug with good efficacy and safety in the treatment of HPV-related genital warts.